Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 | randomized controlled trial | ||||
Mohana, 2020 | retrospective cohort (claims database) | no control group |
Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031 |
||
Thakar, 2021 | randomized controlled trial | other | chloroquine nasal drops |
Thakar A Indian J Med Res 2021 Jan & Feb;153(1 & 2):151-158. 10.4103/ijmr.IJMR_3665_20 |
|
Kanran M, 2020 | randomized controlled trial | other | randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls |